<DOC>
	<DOCNO>NCT01196546</DOCNO>
	<brief_summary>This study ass efficacy safety combination therapy vildagliptin/metformin patient T2DM inadequately control metformin 1,000 mg/day .</brief_summary>
	<brief_title>Efficacy Safety Combination Therapy Vildagliptin/Metformin Patients Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes mellitus patient treat metformin monotherapy 1,000 mg daily least 3 month The patient require HbA1c 6.511.0 % BMI range 2248 kg/m2 Severe uncontrolled Type 2 diabetes mellitus ( HbA1c &gt; 11.0 % ) Acute metabolic diabetes complication ketoacidosis hyperosmolar state ( coma ) within past 6 month Congestive heart failure require pharmacologic treatment Any follow within past 6 month : ( 1 ) myocardial infarction ; ( 2 ) unstable angina ( 3 ) coronary artery bypass surgery percutaneous coronary intervention Liver disease cirrhosis chronic active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin</keyword>
</DOC>